| |
| |
|
| Insider
Information: |
Valamehr Bahram |
| Relationship: |
|
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
158,069 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$616,469 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
158,069 |
|
|
| Total
Value |
$616,469 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
7
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
0
|
6
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -185.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Fate Therapeutics Inc |
FATE |
|
2024-01-09 |
158,069 |
2019-01-07 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| FATE |
Fate Therapeutics Inc |
Chief R&D Officer |
• – – |
2024-01-09 |
4 |
S |
$4.38 |
$49,367 |
D/D |
(11,271) |
158,069 |
0 |
% |
|
| FATE |
Fate Therapeutics Inc |
Chief R&D Officer |
• – – |
2023-01-12 |
4 |
OE |
$1.37 |
$580 |
D/D |
423 |
169,340 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Chief R&D Officer |
• – – |
2023-01-10 |
4 |
S |
$5.24 |
$57,205 |
D/D |
(10,917) |
168,917 |
0 |
% |
|
| FATE |
Fate Therapeutics Inc |
Chief R&D Officer |
• – – |
2022-07-07 |
4 |
AS |
$30.23 |
$518,686 |
D/D |
(17,158) |
179,834 |
0 |
% |
|
| FATE |
Fate Therapeutics Inc |
Chief R&D Officer |
• – – |
2022-07-07 |
4 |
OE |
$2.73 |
$46,841 |
D/D |
17,158 |
196,992 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Chief R&D Officer |
• – – |
2022-07-06 |
4 |
AS |
$30.07 |
$235,809 |
D/D |
(7,842) |
179,834 |
0 |
% |
|
| FATE |
Fate Therapeutics Inc |
Chief R&D Officer |
• – – |
2022-07-06 |
4 |
OE |
$2.73 |
$25,629 |
D/D |
7,842 |
187,676 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Chief R&D Officer |
• – – |
2022-03-14 |
4 |
OE |
$2.73 |
$68,250 |
D/D |
25,000 |
204,834 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Chief R&D Officer |
• – – |
2022-03-14 |
4 |
AS |
$30.36 |
$776,733 |
D/D |
(25,000) |
179,834 |
0 |
% |
|
| FATE |
Fate Therapeutics Inc |
See Remarks |
• – – |
2022-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
33,302 |
179,834 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Chief R&D Officer |
• – – |
2022-01-11 |
4 |
S |
$48.44 |
$221,655 |
D/D |
(4,570) |
146,532 |
0 |
% |
|
| FATE |
Fate Therapeutics Inc |
Chief R&D Officer |
• – – |
2022-01-10 |
4 |
S |
$46.33 |
$259,558 |
D/D |
(5,596) |
151,102 |
0 |
% |
|
| FATE |
Fate Therapeutics Inc |
Chief R&D Officer |
• – – |
2021-12-13 |
4 |
AS |
$45.68 |
$1,191,406 |
D/D |
(25,000) |
156,698 |
0 |
% |
|
| FATE |
Fate Therapeutics Inc |
Chief R&D Officer |
• – – |
2021-12-13 |
4 |
OE |
$2.73 |
$68,250 |
D/D |
25,000 |
181,698 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Chief Development Officer |
• – – |
2021-09-13 |
4 |
AS |
$65.94 |
$1,657,257 |
D/D |
(25,000) |
95,740 |
0 |
% |
|
| FATE |
Fate Therapeutics Inc |
Chief Development Officer |
• – – |
2021-09-13 |
4 |
OE |
$2.73 |
$68,250 |
D/D |
25,000 |
120,740 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Chief Development Officer |
• – – |
2021-03-15 |
4 |
AS |
$90.89 |
$2,308,772 |
D/D |
(25,000) |
95,740 |
0 |
% |
|
| FATE |
Fate Therapeutics Inc |
Chief Development Officer |
• – – |
2021-03-15 |
4 |
OE |
$2.90 |
$72,500 |
D/D |
25,000 |
120,740 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Chief Development Officer |
• – – |
2021-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
18,013 |
95,740 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Chief Development Officer |
• – – |
2021-01-11 |
4 |
S |
$109.65 |
$360,588 |
D/D |
(3,254) |
77,727 |
0 |
% |
|
| FATE |
Fate Therapeutics Inc |
Chief Development Officer |
• – – |
2021-01-08 |
4 |
S |
$114.76 |
$729,552 |
D/D |
(6,230) |
80,981 |
0 |
% |
|
| FATE |
Fate Therapeutics Inc |
Chief Development Officer |
• – – |
2020-12-14 |
4 |
OE |
$2.90 |
$72,500 |
D/D |
25,000 |
112,211 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Chief Development Officer |
• – – |
2020-12-14 |
4 |
AS |
$95.89 |
$2,444,477 |
D/D |
(25,000) |
87,211 |
0 |
% |
|
| FATE |
Fate Therapeutics Inc |
Chief Development Officer |
• – – |
2020-09-14 |
4 |
AS |
$34.65 |
$907,024 |
D/D |
(25,000) |
87,211 |
0 |
% |
|
| FATE |
Fate Therapeutics Inc |
Chief Development Officer |
• – – |
2020-09-14 |
4 |
OE |
$1.69 |
$68,778 |
D/D |
25,000 |
112,211 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
